Myriad Genetics Email Format
Biotechnology Research
・
1,001-2,500 employees
・
Salt Lake City, UT, USA
Myriad Genetics is a molecular diagnostic testing and precision medicine company that develops genetic tests to assess disease risk and guide treatment decisions across medical specialties.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@myriad.com
Company Overview
Industry
Biotechnology Research
Founded
1991
Headquarters
Salt Lake City, UT, USA
Revenue
$500M-$1B
FUNDING Stage
Public
Website
Key Executives
Sam Raha (President and CEO), Ben Wheeler (Chief Financial Officer), Mark S. Verratti (Chief Operating Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Myriad Genetics?
Myriad Genetics uses the firstinitiallast format, so Jane Smith would be jsmith@myriad.com.
What are Myriad Genetics' three main business segments?
Myriad Genetics operates across three segments: Cancer Care Continuum, Prenatal Health, and Mental Health. In Q1 2026, the Cancer Care Continuum generated $120.2 million in revenue, while the Mental Health segment, anchored by the GeneSight test, grew 24% year-over-year.
How does the GeneSight test from Myriad Genetics work?
GeneSight is a pharmacogenomic test offered by Myriad Genetics that analyzes how a patient's genes may affect their response to mental health medications, helping clinicians select treatments more likely to be effective for that individual.
Who leads Myriad Genetics as CEO?
Sam Raha serves as President and CEO of Myriad Genetics. Ben Wheeler is the Chief Financial Officer and Mark S. Verratti is the Chief Operating Officer. You can use Clay to quickly locate and verify contact details for Myriad Genetics leadership when building outreach.
Does Myriad Genetics offer hereditary cancer risk testing?
Yes, Myriad Genetics offers MyRisk, a hereditary cancer test that assesses a patient's genetic risk for 11 different hereditary cancers including breast, ovarian, pancreatic, and prostate cancer, providing clinically actionable insights for patients and providers.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating